JPS6245864B2 - - Google Patents
Info
- Publication number
- JPS6245864B2 JPS6245864B2 JP53158080A JP15808078A JPS6245864B2 JP S6245864 B2 JPS6245864 B2 JP S6245864B2 JP 53158080 A JP53158080 A JP 53158080A JP 15808078 A JP15808078 A JP 15808078A JP S6245864 B2 JPS6245864 B2 JP S6245864B2
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- general formula
- piperidino
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Quinoline Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】
本発明は、一般式
(式中、R1は水素、低級アルキルを示す。R2
が水素であるとき、R3,R4はそれぞれ水素、低
級アルキルを示すか、またはR2とR3,R4の一方
とが互いに結合して単結合を形成するとき、
R3,R4の他方は水素、低級アルキルを示す。R5
は水素、低級アルキルを示す。R6,R7は互いに
結合して隣接した窒素原子とともにモルホリノ、
ピペリジノまたは4−メチルピペラジン−1−イ
ル基を形成する。Xはカルボニル、ヒドロキシメ
チレンを示す。)
で表わされるキノロン誘導体またはその酸付加塩
に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to the general formula (In the formula, R 1 represents hydrogen or lower alkyl. R 2
is hydrogen, R 3 and R 4 each represent hydrogen or lower alkyl, or when R 2 and one of R 3 or R 4 combine with each other to form a single bond,
The other of R 3 and R 4 represents hydrogen or lower alkyl. R5
represents hydrogen or lower alkyl. R 6 and R 7 are bonded to each other and together with the adjacent nitrogen atoms are morpholino,
forming a piperidino or 4-methylpiperazin-1-yl group. X represents carbonyl or hydroxymethylene. ) or an acid addition salt thereof.
上記定義中、低級アルキルとはメチル、エチ
ル、プロピル、ブチルなどがあげられる。 In the above definition, lower alkyl includes methyl, ethyl, propyl, butyl, and the like.
本発明によれば、一般式()の化合物は、た
とえば以下の方法により製造することができる。 According to the present invention, the compound of general formula () can be produced, for example, by the following method.
(a) 一般式
(式中、各記号は前記と同義である。)
で表わされる化合物と、ホルムアルデヒド類お
よび一般式
(式中、各記号は前記と同義である。)
で表わされるアミンの酸付加塩とをマンニツヒ
反応に付すことにより、一般式
(式中、各記号は前記と同義である。)
で表わされる化合物が得られる。(a) General formula (In the formula, each symbol has the same meaning as above.) A compound represented by, formaldehyde and the general formula (In the formula, each symbol has the same meaning as above.) By subjecting the acid addition salt of the amine represented by the following to the Mannitz reaction, the general formula (In the formula, each symbol has the same meaning as above.) A compound represented by the following is obtained.
反応は、マンニツヒ反応の一般的方法、たと
えばアルコール、酢酸などの溶媒中、ホルマリ
ン、パラホルムアルデヒドなどを作用させる方
法などが適用されるが、無水酢酸中、室温から
100℃の範囲で1〜10時間行うことにより好適
に進行する。 The reaction can be carried out using the general Mannitz reaction method, such as using formalin, paraformaldehyde, etc. in a solvent such as alcohol or acetic acid.
The process is preferably carried out at a temperature of 100°C for 1 to 10 hours.
(b) 一般式()の化合物を還元反応に付すこと
により、一般式
(式中、各記号は前記と同義である。)
で表わされる化合物が得られる。(b) By subjecting the compound of general formula () to a reduction reaction, the general formula (In the formula, each symbol has the same meaning as above.) A compound represented by the following is obtained.
反応は、接触水素添加法、錯金属水素化物を
用いる方法など種々の還元反応を用いることが
できるが、たとえば、メタノール、エタノール
などの溶媒中、0〜30℃で水素化ホウ素ナトリ
ウムを用いて還元すると好適に進行する。 Various reduction reactions can be used for the reaction, such as a catalytic hydrogenation method and a method using a complex metal hydride. For example, reduction using sodium borohydride in a solvent such as methanol or ethanol at 0 to 30 °C Then the process will proceed smoothly.
このようにして得られた一般式()の化合物
は常法により塩酸、硫酸、臭化水素酸、マレイン
酸、フマール酸、コハク酸などと処理することに
より、対応する酸付加塩とすることができる。 The compound of general formula () thus obtained can be converted into the corresponding acid addition salt by treating with hydrochloric acid, sulfuric acid, hydrobromic acid, maleic acid, fumaric acid, succinic acid, etc. in a conventional manner. can.
一般式()の化合物およびその酸付加塩は、
鎮痛作用、消炎作用、血小板凝集抑制作用、中枢
抑制作用などの薬理作用を有し、消炎・鎮痛剤、
抗血栓剤などの医薬として、また、それらの合成
中間体として有用である。 Compounds of general formula () and acid addition salts thereof are:
It has pharmacological effects such as analgesic effect, anti-inflammatory effect, platelet aggregation inhibitory effect, and central nervous system depressant effect, and is an anti-inflammatory and analgesic agent.
It is useful as a medicine such as an antithrombotic agent, and as a synthetic intermediate thereof.
本発明の化合物を医薬として用いる場合、それ
自体または適宜の薬理的に許容される担体、賦形
剤、希釈剤などと混合し、散剤、顆粒剤、錠剤、
カプセル剤、注射剤などの形態で経口的または非
経口的に投与できる。投与量は対象疾患、症状、
用いる化合物によつても異なるが、経口投与の場
合、通常成人1日あたり1〜1000mg程度である。 When the compound of the present invention is used as a medicine, it can be used as a medicine or mixed with appropriate pharmacologically acceptable carriers, excipients, diluents, etc., and can be used as a powder, granule, tablet, etc.
It can be administered orally or parenterally in the form of capsules, injections, etc. The dosage depends on the target disease, symptoms,
Although it varies depending on the compound used, in the case of oral administration, the dose is usually about 1 to 1000 mg per day for adults.
次に、本発明を実施例をあげて具体的に説明す
る。 Next, the present invention will be specifically explained with reference to examples.
実施例 1
ピペリジン塩酸塩9.0gと37%ホルマリン5ml
とを混ぜ、80℃で無水酢酸35mlを30分を要して適
下する。1時間80〜90℃に保つた後、1−メチル
−6−プロピオニル−1,2,3,4−テトラヒ
ドロキノリン−2−オン11gを加え、70℃で1時
間保つ。反応終了後、アセトン40mlを加え、5分
間還流する。冷却後、結晶を取し、メタノール
から再結晶すると、1−メチル−6−(3−ピペ
リジノ−2−メチルプロピオニル)−1,2,
3,4−テトラヒドロキノリン−2−オン・塩酸
塩9.5gが得られる。融点222〜224℃
◎ 6−(3−モルホリノ−2−メチルプロピオ
ニル)−1,2,3,4−テトラヒドロキノリ
ン−2−オン・塩酸塩 融点194〜195℃
◎ 6−(3−ピペリジノ−2−メチルプロピオ
ニル)−1,2,3,4−テトラヒドロキノリ
ン−2−オン・塩酸塩 融点194〜195℃
◎ 1−メチル−6−(3−モルホリノ−2−メ
チルプロピオニル)−1,2,3,4−テトラ
ヒドロキノリン−2−オン・塩酸塩 融点206
〜207℃
◎ 1−メチル−6−〔3−(4−メチルピペラジ
ン−1−イル)−2−メチルプロピオニル〕−
1,2,3,4−テトラヒドロキノリン−2−
オン・2塩酸塩 融点195〜198℃(分解)
◎ 4−メチル−6−(3−ピペリジノ−2−メ
チルプロピオニル)−1,2−ジヒドロキノリ
ン−2−オン・塩酸塩 融点215〜216℃
◎ 1,4−ジメチル−6−(3−ピペリジノプ
ロピオニル)−1,2−ジヒドロキノリン−2
−オン・塩酸塩・1/2水和物 融点221〜223℃
◎ 1,4−ジメチル−6−(3−ピペリジノ−
2−メチルプロピオニル)−1,2−ジヒドロ
キノリン−2−オン・塩酸塩 融点191〜193℃
実施例 2
1−メチル−6−(3−ピペリジノ−2−メチ
ルプロピオニル)−1,2,3,4−テトラヒド
ロキノリン−2−オン・塩酸塩8.6gをメタノー
ル100mlに溶かし、氷冷下、水素化ホウ素ナトリ
ウム3gを少量ずつ加え、次いで室温に3時間保
つ。反応後、減圧下に濃縮し、残留物に水を加え
て分解し、酢酸エチル100mlで抽出する。芒硝で
乾燥後、減圧下に溶媒を留去し、アルコール塩酸
を用いて塩酸塩とする。得られた結晶をエタノー
ルから再結晶すると、1−メチル−6−(3−ピ
ペリジノ−1−ヒドロキシ−2−メチルプロピ
ル)−1,2,3,4−テトラヒドロキノリン−
2−オン・塩酸塩5.6gが得られる。融点214〜
215℃
以下同様にして次の化合物が合成される。Example 1 9.0 g of piperidine hydrochloride and 5 ml of 37% formalin
Mix and add 35 ml of acetic anhydride at 80℃ over 30 minutes. After keeping at 80-90°C for 1 hour, 11 g of 1-methyl-6-propionyl-1,2,3,4-tetrahydroquinolin-2-one was added and kept at 70°C for 1 hour. After the reaction is complete, add 40 ml of acetone and reflux for 5 minutes. After cooling, the crystals were collected and recrystallized from methanol to give 1-methyl-6-(3-piperidino-2-methylpropionyl)-1,2,
9.5 g of 3,4-tetrahydroquinolin-2-one hydrochloride are obtained. Melting point 222-224℃ ◎ 6-(3-morpholino-2-methylpropionyl)-1,2,3,4-tetrahydroquinolin-2-one hydrochloride Melting point 194-195℃ ◎ 6-(3-Piperidino-2 1-Methyl-6-(3-morpholino-2-methylpropionyl)-1,2,3 ,4-tetrahydroquinolin-2-one hydrochloride Melting point 206
~207℃ ◎ 1-Methyl-6-[3-(4-methylpiperazin-1-yl)-2-methylpropionyl]-
1,2,3,4-tetrahydroquinoline-2-
4-methyl-6-(3-piperidino-2-methylpropionyl)-1,2-dihydroquinolin-2-one hydrochloride Melting point 215-216℃ ◎ 1,4-dimethyl-6-(3-piperidinopropionyl)-1,2-dihydroquinoline-2
1,4-dimethyl-6-(3-piperidino-
2-Methyl-6-(3-piperidino-2-methylpropionyl)-1,2,3, Dissolve 8.6 g of 4-tetrahydroquinolin-2-one hydrochloride in 100 ml of methanol, add 3 g of sodium borohydride little by little under ice cooling, and then keep at room temperature for 3 hours. After the reaction, concentrate under reduced pressure, add water to decompose the residue, and extract with 100 ml of ethyl acetate. After drying with Glauber's salt, the solvent is distilled off under reduced pressure, and the hydrochloride is prepared using alcoholic hydrochloric acid. When the obtained crystals are recrystallized from ethanol, 1-methyl-6-(3-piperidino-1-hydroxy-2-methylpropyl)-1,2,3,4-tetrahydroquinoline-
5.6 g of 2-one hydrochloride are obtained. Melting point 214~
The following compounds are synthesized in the same manner below 215°C.
◎ 6−(3−モルホリノ−1−ヒドロキシ−2
−メチルプロピオニル)−1,2,3,4−テ
トラヒドロキノリン−2−オン・塩酸塩 融点
210℃(分解)◎ 6-(3-morpholino-1-hydroxy-2
-Methylpropionyl)-1,2,3,4-tetrahydroquinolin-2-one hydrochloride Melting point
210℃ (decomposition)
Claims (1)
が水素であるとき、R3,R4はそれぞれ水素、低
級アルキルを示すか、またはR2とR3,R4の一方
とが互いに結合して単結合を形成するとき、
R3,R4の他方は水素、低級アルキルを示す。R5
は水素、低級アルキルを示す。R6,R7は互いに
結合して隣接した窒素原子とともにモルホリノ、
ピペリジノまたは4−メチルピペラジン−1−イ
ル基を形成する。Xはカルボニル、ヒドロキシメ
チレンを示す。) で表わされるキノロン誘導体。[Claims] 1. General formula (In the formula, R 1 represents hydrogen or lower alkyl. R 2
is hydrogen, R 3 and R 4 each represent hydrogen or lower alkyl, or when R 2 and one of R 3 or R 4 combine with each other to form a single bond,
The other of R 3 and R 4 represents hydrogen or lower alkyl. R5
represents hydrogen or lower alkyl. R 6 and R 7 are bonded to each other and together with the adjacent nitrogen atoms are morpholino,
forming a piperidino or 4-methylpiperazin-1-yl group. X represents carbonyl or hydroxymethylene. ) A quinolone derivative represented by
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15808078A JPS5583749A (en) | 1978-12-19 | 1978-12-19 | Quinolone derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP15808078A JPS5583749A (en) | 1978-12-19 | 1978-12-19 | Quinolone derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5583749A JPS5583749A (en) | 1980-06-24 |
| JPS6245864B2 true JPS6245864B2 (en) | 1987-09-29 |
Family
ID=15663850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP15808078A Granted JPS5583749A (en) | 1978-12-19 | 1978-12-19 | Quinolone derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5583749A (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH17194A (en) * | 1980-03-06 | 1984-06-19 | Otsuka Pharma Co Ltd | Novel carbostyril derivatives,and pharmaceutical composition containing the same |
| JPS57142972A (en) * | 1981-02-27 | 1982-09-03 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| JPS5843952A (en) * | 1981-09-09 | 1983-03-14 | Otsuka Pharmaceut Co Ltd | Preparation of carbostyril derivative |
| US4578381A (en) * | 1982-07-05 | 1986-03-25 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US4792561A (en) * | 1986-05-29 | 1988-12-20 | Syntex (U.S.A.) Inc. | Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors |
| ES2053480T3 (en) * | 1986-07-31 | 1994-08-01 | Otsuka Pharma Co Ltd | A PROCEDURE FOR PREPARING A CARBOESTIRILE DERIVATIVE. |
| JPH01221315A (en) * | 1988-02-24 | 1989-09-04 | Otsuka Pharmaceut Co Ltd | Central nervous system depressant |
| JPH0249769A (en) * | 1989-06-26 | 1990-02-20 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52118474A (en) * | 1976-03-31 | 1977-10-04 | Otsuka Pharmaceut Co Ltd | Alpha-substituted aminoalkanyol-3,4-dihydrocarbostyril derivatives and method of preparing the same |
-
1978
- 1978-12-19 JP JP15808078A patent/JPS5583749A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5583749A (en) | 1980-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2656699B2 (en) | Substituted benzylaminoquinuclidine | |
| US4021485A (en) | N,N'-bis-[(β-hydroxy-β-phenyl)-ethyl]-polymethylenediamines and salts thereof | |
| HU196376B (en) | Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds | |
| EP0028381B1 (en) | Azepinoindoles, process for their production and pharmaceutical compositions containing them | |
| JPH0625091B2 (en) | Dihydrodibenzocycloheptylidene-ethylamine derivative, its production method and pharmaceutical composition | |
| JPS6245864B2 (en) | ||
| US4375479A (en) | Indanyl derivatives and use | |
| JPS6033818B2 (en) | Manufacturing method for new naphthalene derivatives | |
| JPH05500822A (en) | Orally active non-addictive analgesic | |
| JPS58159492A (en) | Cholinantein derivative, manufacture and use | |
| CA2120997A1 (en) | Triazolopyridazine derivatives, their production and use | |
| JPH02134347A (en) | Tetrahydronaphthalene and indane derivative | |
| JPS58121274A (en) | N-pyridyl-amide of 1-phenyl-cyclopentane carboxylic acid, manufacture and medicine | |
| US3491097A (en) | 3-(piperazinoalkyl)-pyrazoles | |
| JPS5849369A (en) | Novel imidazole compound, manufacture and analgesic antipuretic antiinflammatory drug containing same as major component | |
| JPS5943460B2 (en) | Method for producing 2-amino-6-dialkylaminodihydropyridine | |
| JPS61148173A (en) | Novel amine and its salt | |
| JPH01503777A (en) | Fused alicyclic amino alcohols | |
| US3414574A (en) | Certain pyrimido (4, 5-b) indoles and intermediates employed in their preparation | |
| JPS5823664A (en) | Novel n-aromatic group heterocyclic group substituted piperidine, piperazine and homopiperazine derivatives, manufacture and drugs | |
| US3505343A (en) | 1-lower alkyl-4-(2'-hydroxylower alkyl)-4-piperidinols and lower alkyl acid esters thereof | |
| US20100144799A1 (en) | Optical enantiomers of phenyramidol and process for chiral synthesis | |
| JPH01311064A (en) | Salicylic acid derivative | |
| JPH062748B2 (en) | Novel hydantoin derivative and pharmaceutical composition containing the compound as an active ingredient | |
| US3951984A (en) | 3-Benzazocine compounds |